Palle Christophersen
Founder at SANA AB
Net worth: 145 021 $ as of 29/04/2024
Palle Christophersen active positions
Companies | Position | Start | End |
---|---|---|---|
SANA AB | Chief Tech/Sci/R&D Officer | 31/12/2013 | - |
Founder | 31/12/2010 | - | |
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Chief Tech/Sci/R&D Officer | - | - |
Career history of Palle Christophersen
Former positions of Palle Christophersen
Companies | Position | Start | End |
---|---|---|---|
NTG NORDIC TRANSPORT GROUP A/S | Corporate Officer/Principal | 27/05/2010 | 31/12/2011 |
Training of Palle Christophersen
University of Copenhagen | Doctorate Degree |
Statistics
International
Denmark | 5 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 1 |
Founder | 1 |
Sectoral
Transportation | 2 |
Health Technology | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
NTG NORDIC TRANSPORT GROUP A/S | Transportation |
SANA AB | Health Technology |
Private companies | 1 |
---|---|
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Commercial Services |
- Stock Market
- Insiders
- Palle Christophersen
- Experience